CureVac (NASDAQ:CVAC) Shares Gap Up – Should You Buy?

CureVac (NASDAQ:CVAC) shares gapped up before the market opened on Friday . The stock had previously closed at $3.40, but opened at $3.68. CureVac shares last traded at $3.71, with a volume of 261,665 shares changing hands.

Wall Street Analyst Weigh In

Several analysts have commented on CVAC shares. UBS Group lowered their target price on shares of CureVac from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday. JMP Securities reaffirmed a “market outperform” rating and issued a $16.00 price objective on shares of CureVac in a research report on Friday, February 14th.

CureVac Trading Up 4.7 %

The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The business’s fifty day moving average is $3.06 and its 200-day moving average is $3.20. The stock has a market capitalization of $798.64 million, a PE ratio of 6.47 and a beta of 2.48.

CureVac (NASDAQ:CVAC) last announced its quarterly earnings data on Thursday, April 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The company had revenue of $15.44 million for the quarter, compared to analysts’ expectations of $6.40 million. CureVac had a net margin of 20.72% and a return on equity of 21.98%. As a group, analysts anticipate that CureVac will post 0.72 EPS for the current fiscal year.

Hedge Funds Weigh In On CureVac

Several hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC increased its position in CureVac by 10.3% during the 4th quarter. Geode Capital Management LLC now owns 241,750 shares of the company’s stock worth $824,000 after purchasing an additional 22,491 shares in the last quarter. Barclays PLC acquired a new stake in shares of CureVac in the third quarter worth $67,000. Jane Street Group LLC raised its stake in shares of CureVac by 239.0% in the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock valued at $235,000 after acquiring an additional 55,867 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of CureVac by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company’s stock valued at $162,000 after acquiring an additional 4,425 shares in the last quarter. Finally, Quadrant Capital Group LLC boosted its position in CureVac by 61.8% during the 4th quarter. Quadrant Capital Group LLC now owns 50,016 shares of the company’s stock worth $171,000 after purchasing an additional 19,098 shares during the period. 17.26% of the stock is owned by institutional investors and hedge funds.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.